|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004927,
umls-concept:C0006104,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0085762,
umls-concept:C0211726,
umls-concept:C0441889,
umls-concept:C0442805,
umls-concept:C1172779,
umls-concept:C1414512,
umls-concept:C1427405
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-5-29
|
|
pubmed:abstractText |
A major clinical concern with the use of cannabinoid receptor 1 (CB1) direct agonists is that these compounds increase alcohol drinking and drug abuse-related behaviours. As an alternative approach, CB1-receptor-mediated activity can be facilitated by increasing anandamide levels with the use of hydrolase fatty acid amide hydrolase (FAAH) inhibitors.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic alpha-Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Amidohydrolases,
http://linkedlifedata.com/resource/pubmed/chemical/Arachidonic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Benzamides,
http://linkedlifedata.com/resource/pubmed/chemical/Carbamates,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Polyunsaturated Alkamides,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Cannabinoid, CB1,
http://linkedlifedata.com/resource/pubmed/chemical/Yohimbine,
http://linkedlifedata.com/resource/pubmed/chemical/anandamide,
http://linkedlifedata.com/resource/pubmed/chemical/cyclohexyl carbamic acid...,
http://linkedlifedata.com/resource/pubmed/chemical/fatty-acid amide hydrolase
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0033-3158
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
198
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
449-60
|
|
pubmed:dateRevised |
2011-8-3
|
|
pubmed:meshHeading |
pubmed-meshheading:18446329-Adrenergic alpha-Antagonists,
pubmed-meshheading:18446329-Alcohol Drinking,
pubmed-meshheading:18446329-Alcoholism,
pubmed-meshheading:18446329-Amidohydrolases,
pubmed-meshheading:18446329-Animals,
pubmed-meshheading:18446329-Anxiety,
pubmed-meshheading:18446329-Arachidonic Acids,
pubmed-meshheading:18446329-Benzamides,
pubmed-meshheading:18446329-Brain Chemistry,
pubmed-meshheading:18446329-Carbamates,
pubmed-meshheading:18446329-Conditioning, Operant,
pubmed-meshheading:18446329-Cues,
pubmed-meshheading:18446329-Electroshock,
pubmed-meshheading:18446329-Enzyme Inhibitors,
pubmed-meshheading:18446329-Extinction, Psychological,
pubmed-meshheading:18446329-Male,
pubmed-meshheading:18446329-Polyunsaturated Alkamides,
pubmed-meshheading:18446329-Rats,
pubmed-meshheading:18446329-Rats, Wistar,
pubmed-meshheading:18446329-Receptor, Cannabinoid, CB1,
pubmed-meshheading:18446329-Recurrence,
pubmed-meshheading:18446329-Reinforcement Schedule,
pubmed-meshheading:18446329-Self Administration,
pubmed-meshheading:18446329-Stress, Psychological,
pubmed-meshheading:18446329-Yohimbine
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat.
|
|
pubmed:affiliation |
Department of Experimental Medicine and Public Health, University of Camerino, Via Madonna delle Carceri, 62032 Camerino, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
